{
    "nct_id": "NCT02939183",
    "official_title": "(INTREPID-1) A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Oprozomib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",
    "inclusion_criteria": "Inclusion criteria\n\n* Participant must have a pathologically documented, definitively diagnosed, multiple myeloma relapse, or refractory progressive disease after at least 2 lines of therapy for multiple myeloma. Prior therapeutic treatment or regimens must include a proteasome inhibitor and lenalidomide.\n* Participant must be willing and able to undergo bone marrow aspirate per protocol (with or without bone marrow biopsy per institutional guidelines).\n* Measurable disease (assessed within 28 days prior to day 1).\n* Eastern Cooperative Oncology Group (ECOG) performance status of <= 2.\n* Other Inclusion Criteria May Apply\n\nExclusion Criteria\n\n* Currently receiving treatment in another investigational device or drug study, or less than 28 days or 5 half-lives whichever is shorter since ending treatment on another investigational device or drug study(s).\n* Previously received an allogeneic stem cell transplant and the occurrence of one or more of the following: received the transplant within 6 months prior to study day 1; received immunosuppressive therapy within the last 3 months prior to study day 1; having signs or symptoms of acute or chronic graft-versus-host disease.\n* Autologous stem cell transplant < 90 days prior to study day 1.\n* Multiple myeloma with IgM subtype.\n* POEM syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes).\n* Plasma cell leukemia (> 2.0 X10^9/L circulating plasma cells by standard differential).\n* Waldenstrom's macroglobulinemia.\n* Other Exclusion Criteria May Apply\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "",
    "miscellaneous_criteria": ""
}